ChemBridge

Physiomics Announces License Agreement with Eli Lilly

Date Posted: Thursday, April 02, 2009

Print Email to a friend

Under the terms of the agreement,Physiomics will license to Lilly a customised version of its “ModelPlayer” for in silico simulations of unspecified anticancer drugs and Lilly will have the option to purchase additional licenses.

Physiomics’ “ModelPlayer” is a stand-alone simulation platform used for in-house model development that can be out-licensed to partners to allow them to perform their own simulations using Physiomics’ models. It incorporates a range of features necessary for developing and calibrating models and simulating anticancer drugs.

Dr Christophe Chassagnole, COO of Physiomics, said:
‘We are delighted with the continued interest shown by Lilly in Physiomics’
technology. We hope that the capability for Lilly scientists to directly use Physiomics’ models will strengthen the quality of the interactions within our ongoing research collaborations. This is also an important commercial and technical milestone for Physiomics as this is the first time that we have out-licensed our technology.’

Further Information: http//www.physiomics-plc.com



Related news from our archive

Major Technical Innovation in Drug and Tumour Modelling Results
Physiomics' SystemCell® software grows complex virtual cells to mimic the experimental behaviour of many cancer cells and their responses to drugs.

Physiomics Announces License Agreement with Eli Lilly
Lilly licenses a customized version of Physiomics’ ModelPlayer for in silico simulations of unspecified anticancer drugs.